Abstract:IMPORTANCE Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC). OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING, AND PARTICIPANTS The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical trial designed to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. Patients from 31 grade-A tertiary hospitals in China were enrolled between March 1, 2015, and August 31, 2016. Those aged 18 to 75 years who had histologically or cytologically confirmed NSCLC were eligible (n = 606), and those who had centrally located squamous cell carcinoma with cavitary features or brain metastases that were uncontrolled or controlled for less than 2 months were excluded. Patients (n = 440) were randomly assigned in a 2-to-1 ratio to receive either 12 mg/d of anlotinib or a matched placebo. All cases were treated with study drugs at least once in accordance with the intention-to-treat principle. MAIN OUTCOMES AND MEASURES The primary end point was overall survival. The secondary end points were progression-free survival, objective response rate, disease control rate, quality of life, and safety. RESULTS In total, 439 patients were randomized, 296 to the anlotinib group (106 [36.1%] were female and 188 [64.0%] were male, with a mean [SD] age of 57.9 [9.1] years) and 143 to the placebo group (46 [32.2%] were female and 97 [67.8%] were male, with a mean [SD] age of 56.8 [9.1] years). Overall survival was significantly longer in the anlotinib group (median, 9.6 months; 95% CI, 8.2-10.6) than the placebo group (median, 6.3 months; 95% CI, 5.0-8.1), with a hazard ratio (HR) of 0.68 (95% CI, 0.54-0.87; P =.002). A substantial increase in progression-free survival was noted in the anlotinib group compared with the placebo group (median, 5.4 months [95% CI, 4.4-5.6] vs 1.4 months [95% CI, 1.1-1.5]; HR, 0.25 [95% CI, 0.19-0.31]; P <.001). Considerable improvement in objective response rate and disease control rate was observed in the anlotinib group over the placebo group. The most common grade 3 or higher adverse events in the anlotinib arm were hypertension and hyponatremia. CONCLUSIONS AND RELEVANCE Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. This finding suggests that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC.

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

Level of Activated Circulating Endothelial Cells to Predict Progression-Free Survival of Anlotinib Treatment in Patients with NSCLC: Analysis on ALTER-0303 Study.

Association Between Anlotinib Trough Plasma Concentration and Treatment Outcomes in Advanced Non-Small-cell Lung Cancer

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy.

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

P1.03-16 Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer Via Blocking CCL2 Expression

Predictive and Prognostic Significance of Circulating Endothelial Cells in Advanced Non-Small Cell Lung Cancer Patients

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC As Third-Line Treatment: Data from Trial ALTER 0303

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.

Prognostic Factors of Refractory NSCLC Patients Receiving Anlotinib Hydrochloride As the Third- or Further-Line Treatment.

P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy As First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Effect of Anlotinib As a Third-Line or Further Treatment on Overall Survival of Patients with Advanced Non–Small Cell Lung Cancer

Effect of Anlotinib As a Third‐ or Further‐line Therapy in Advanced Non‐small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial

P3.03-017 Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial

Efficacy and Safety Analysis of Anlotinib Combined with PD-1 Inhibitors in Advanced Non-Small Cell Lung Cancer: a Retrospective Cohort Study

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer